Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product liability House/Senate conference unlikely until next year.

This article was originally published in The Gray Sheet

Executive Summary

PRODUCT LIABILITY HOUSE/SENATE CONFERENCE NOT LIKELY UNTIL NEXT YEAR due to Senate leadership concerns that attempting recon-ciliation now would result in a conference bill that retains much of the character of the House's more rigorous version. The House version (HR 956), passed March 10, differs from the Senate legislation (S 565), approved May 10, in that it includes both an FDA defense and a cap of non-economic ("pain and suffering") damages at $250,000 for health care lawsuits which would supersede state laws that set a higher cap on non-economic damage awards.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel